huperzine a has been researched along with Epilepsy in 3 studies
huperzine A: RN given refers to 5R-(5alpha,9beta,11E)-isomer; structure given in first source
huperzine A : A sesquiterpene alkaloid isolated from a club moss Huperzia serrata that has been shown to exhibit neuroprotective activity. It is also an effective inhibitor of acetylcholinesterase and has attracted interest as a therapeutic candidate for Alzheimer's disease.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this review, we examine recently approved epilepsy drugs based on natural product (NP) such as cannabidiol (CBD) and rapamycin, as well as NP-based epilepsy drug candidates still in clinical development, such as huperzine A." | 5.41 | Natural product-derived therapies for treating drug-resistant epilepsies: From ethnopharmacology to evidence-based medicine. ( Challal, S; Crawford, AD; Esguerra, CV; Langlois, M; Skalicka-Woźniak, K; Skiba, A; Wolfender, JL, 2023) |
| "Huperzine A (HupA) is an acetylcholinesterase (AChE) inhibitor extracted from Huperzia Serrata, a firmoss, which has been used for various diseases in traditional Chinese medicine for fever and inflammation." | 2.53 | Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research. ( Damar, U; Gersner, R; Johnstone, JT; Rotenberg, A; Schachter, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Challal, S | 1 |
| Skiba, A | 1 |
| Langlois, M | 1 |
| Esguerra, CV | 1 |
| Wolfender, JL | 1 |
| Crawford, AD | 1 |
| Skalicka-Woźniak, K | 1 |
| Damar, U | 2 |
| Gersner, R | 2 |
| Johnstone, JT | 2 |
| Schachter, S | 2 |
| Rotenberg, A | 2 |
2 reviews available for huperzine a and Epilepsy
| Article | Year |
|---|---|
Natural product-derived therapies for treating drug-resistant epilepsies: From ethnopharmacology to evidence-based medicine.
Topics: Animals; Anticonvulsants; Biological Products; Cannabidiol; Drug Resistant Epilepsy; Epilepsy; Ethno | 2023 |
Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research.
Topics: Alkaloids; Animals; Anticonvulsants; Cholinesterase Inhibitors; Epilepsy; Humans; Neuroprotective Ag | 2016 |
1 other study available for huperzine a and Epilepsy
| Article | Year |
|---|---|
Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetic | 2017 |